Literature DB >> 34153307

Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex.

L Angelica Lerma1, George R Schade2, Maria S Tretiakova3.   

Abstract

Renal cell tumors with oncocytic phenotypes represent a daily challenge, with several novel, emerging, and provisional entities enriching the diagnostic repertoire. Eosinophilic solid and cystic renal cell carcinoma (ESC-RCC), low-grade oncocytic tumor (LOT), and eosinophilic vacuolated tumor (EVT) have been recognized as unique entities, although their distinctive nature remains controversial. Although most of these tumors are sporadic, rare reports of similar tumors in tuberous sclerosis complex (TSC) have been published. We describe multifocal, often bilateral, tumors in six patients without personal or family history of syndromic diseases. More than 60 tumors in various combinations were identified in 10 nephrectomies and one biopsy encompassing ESC-RCC (n = 6), LOT (n = 14), EVT (n = 1), clear cell RCC with fibromyomatous stroma (n = 12), clear cell RCC (n = 2), angiomyolipomas (AMLs; n > 20), unclassified renal cell tumors (n = 2), papillary adenomas (n = 4), and renomedullary interstitial cell tumor (n = 1). TSC1 germline pathogenic mutations were confirmed in two patients. A tumor without germline testing in a third patient revealed TSC1 biallelic inactivation. Two additional patients had molecular testing, which excluded common renal mutations and syndromes. We provide the first evidence of co-existence in the same organ and unequivocal relatedness of ESC-RCC, EVT, and LOT. End-stage renal disease was present in three of six patients with precursor lesions to all above tumors within adjacent renal parenchyma. In conclusion, identification of multifocal tumors with TSC-like morphology, especially in association with AMLs, could be the first manifestation of clinically silent TSC guiding clinical recommendations for further genetic testing and/or treatment recommendations.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoma, renal cell/genetics; Carcinoma, renal cell/pathology; Kidney neoplasms/genetics; Kidney neoplasms/pathology; Tuberous sclerosis

Mesh:

Substances:

Year:  2021        PMID: 34153307     DOI: 10.1016/j.humpath.2021.06.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

Review 1.  Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.

Authors:  Mehdi Mansoor; Farshid Siadat; Kiril Trpkov
Journal:  Histol Histopathol       Date:  2022-02-14       Impact factor: 2.303

2.  Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.

Authors:  Hui-Zhi Zhang; Qiu-Yuan Xia; Shu-Yan Wang; Meng-Jie Shi; Su-Ying Wang
Journal:  Virchows Arch       Date:  2022-01-31       Impact factor: 4.064

Review 3.  Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities.

Authors:  Ondrej Hes; Kiril Trpkov
Journal:  Mod Pathol       Date:  2022-03-10       Impact factor: 8.209

Review 4.  Renal Cell Carcinoma in Tuberous Sclerosis Complex.

Authors:  Elizabeth P Henske; Kristine M Cornejo; Chin-Lee Wu
Journal:  Genes (Basel)       Date:  2021-10-08       Impact factor: 4.141

Review 5.  TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background.

Authors:  Kristyna Pivovarcikova; Reza Alaghehbandan; Tomas Vanecek; Riuko Ohashi; Tomas Pitra; Ondrej Hes
Journal:  Biomedicines       Date:  2022-01-29

Review 6.  Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates.

Authors:  Reza Alaghehbandan; Christopher G Przybycin; Virginie Verkarre; Rohit Mehra
Journal:  Asian J Urol       Date:  2021-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.